Top

Quality of Life Research

Gepubliceerd in:

01-09-2009

Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema

Auteurs: Margaret K. Vernon, Anne M. Rentz, Kathleen W. Wyrwich, Martha V. White, Aurelie Grienenberger

Gepubliceerd in: Quality of Life Research | Uitgave 7/2009

Abstract

Purpose

Hereditary angioedema (HAE) is a rare disorder characterized by highly variable, acute attacks of swelling at various anatomical locations. Clinical measures do not adequately assess the diversity of symptoms characteristic of an attack. Two disease-specific, patient-reported outcome measures were developed to comprehensively capture symptom severity and change: the Treatment Outcome Score (TOS) and the Mean Symptom Complex Severity (MSCS) score.

Methods

This study comprised a secondary analysis of pooled data from a randomized controlled trial to evaluate the psychometric properties, including reliability and validity, and minimally important difference (MID) of the TOS and MSCS score.

Results

HAE patients (n = 73) had a mean age of 33 years, and 60% were female. Test–retest evaluation demonstrated moderate to substantial agreement (ICCs = 0.53 for TOS; 0.62 for MSCS score). The TOS and change in MSCS score were moderately to highly correlated with a Global Improvement Measure at 4 h (TOS: r = 0.90; MSCS: r = −0.59). Anchor- and distribution-based analyses suggested that conservative estimates for MID are 30 points for TOS and −0.30 points for 4-h change in MSCS score.

Conclusions

The psychometric tests performed here provide evidence of the reliability and validity of the TOS and MSCS for evaluating symptom severity and change in HAE patients. The TOS and MSCS score provide an example of measurement methodology that may be used to precisely capture symptom severity and change in a disease characterized by acute attacks.

vorige artikel Italian translation of the Manchester-Oxford Foot Questionnaire, with re-assessment of reliability and validity

volgende artikel Reliability and validity of an instrument for assessing patients’ perceptions about medications for diabetes: the PAM-D

Davis, A. E., 3rd. (2004). Biological effects of C1 inhibitor. Drug News & Perspectives, 17(7), 439–446.CrossRef

Huang, Y. T., Lin, Y. Z., Wu, H. L., Chiu, T. F., Lee, K. M., Tsai, H. Y., et al. (2005). Hereditary angioedema: A family study. Asian Pacific Journal of Allergy and Immunology, 23(4), 227–233.PubMed

Tosi, M. (1998). Molecular genetics of C1 inhibitor. Immunobiology, 199(2), 358–365.PubMed

Cicardi, M., & Agostoni, A. (1996). Hereditary angioedema. New England Journal of Medicine, 334(25), 1666–1667.PubMedCrossRef

Bracho, F. A. (2005). Hereditary angioedema. Current Opinion in Hematology, 12(6), 493–498.PubMedCrossRef

Bork, K., Meng, G., Staubach, P., & Hardt, J. (2006). Hereditary angioedema: New findings concerning symptoms, affected organs, and course. American Journal of Medicine, 119(3), 267–274.PubMedCrossRef

Bork, K., Hardt, J., Schicketanz, K. H., & Ressel, N. (2003). Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Archives of Internal Medicine, 163(10), 1229–1235.PubMedCrossRef

Gompels, M. M., Lock, R. J., Abinun, M., Bethune, C. A., Davies, G., Grattan, C., et al. (2005). C1 inhibitor deficiency: Consensus document. Clinical and Experimental Immunology, 139(3), 379–394.PubMedCrossRef

Levy, J. H., & O’Donnell, P. S. (2006). The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opinion on Investigational Drugs, 15(9), 1077–1090.PubMedCrossRef

10.

Hays, R., & Revicki, D. A. (2005). Reliability and validity (including responsiveness). In R. Hays & D. A. Revicki (Eds.), Assessing quality of life in clinical trials (pp. 25–39). New York, NY: Oxford University Press.

11.

Revicki, D. A., Osoba, D., Fairclough, D., Barofsky, I., Berzon, R., Leidy, N. K., et al. (2000). Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Quality of Life Research, 9(8), 887–900.PubMedCrossRef

12.

Leidy, N. K., Revicki, D. A., & Geneste, B. (1999). Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health, 2(2), 113–127.PubMedCrossRef

13.

Vernon, M. K., Rentz, A., White, M., & Schmalbach, T. (2007). Content validity and usability of the treatment outcome score and mean complex severity score: New electronic pros to assess symptom severity and improvement in hereditary angioedema. In 14th Annual Conference of the International Society for Quality of Life Research, Toronto, Ontario, Canada.

14.

White, M., Vernon, M. K., Rentz, A., Beck, T. R., & Roberts, J. (2007). Development of a Patient-Reported Outcome (PRO) Measure to Assess Symptom Severity and Change in Hereditary Angioedema (HAE). The American College of Allergy, Asthma, & Immunology Annual Scientific Meeting, Dallas, TX.

15.

Vernon, M. K., Rentz, A. M., White, M. V., & Grienenberger, A. (2008). Validation of a Patient-Reported Outcome Measure to Assess Response to Treatment in Hereditary Angioedema. American College of Asthma, Allergy, & Immunology, Seattle, WA.

16.

Schneider, L., Lumry, W., Vegh, A., Williams, A. H., & Schmalbach, T. (2007). Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor. The Journal of Allergy and Clinical Immunology, 120(2), 416–422.PubMedCrossRef

17.

Kunschak, M., Engl, W., Maritsch, F., Rosen, F. S., Eder, G., Zerlauth, G., et al. (1998). A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion, 38(6), 540–549.PubMedCrossRef

18.

Waytes, A. T., Rosen, F. S., & Frank, M. M. (1996). Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. New England Journal of Medicine, 334(25), 1630–1634.PubMedCrossRef

19.

Saengpanich, S., deTineo, M., Naclerio, R. M., & Baroody, F. M. (2003). Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis. Archives of Otolaryngology: Head & Neck Surgery, 129(5), 557–562.CrossRef

20.

Simons, F. E., Prenner, B. M., & Finn, A., Jr. (2003). Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. The Journal of Allergy and Clinical Immunology, 111(3), 617–622.PubMedCrossRef

21.

Small, C. B., Hernandez, J., Reyes, A., Schenkel, E., Damiano, A., Stryszak, P., et al. (2005). Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. The Journal of Allergy and Clinical Immunology, 116(6), 1275–1281.PubMedCrossRef

22.

Patrick, D. L., Burke, L. B., Powers, J. H., Scott, J. A., Rock, E. P., Dawisha, S., et al. (2007). Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health, 10(Suppl 2), S125–S137.PubMedCrossRef

23.

Deyo, R. A., Diehr, P., & Patrick, D. L. (1991). Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials, 12(4 Suppl), 142S–158S.PubMedCrossRef

24.

Streiner, D. L., & Norman, G. R. (2003). Health measurement scales. Oxford: Oxford University Press.

25.

Scientific Advisory Committee of the Medical Outcomes Trust. (2002). Assessing health status and quality-of-life instruments: Attributes and review criteria. Quality of Life Research, 11(3), 193–205.CrossRef

26.

Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159–174.PubMedCrossRef

27.

Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Erlbaum.

28.

Sloan, J. A., Symonds, T., Vargas-Chanes, D., & Friedly, B. (2003). Practical guidelines for assessing the clinical significance of heath related quality of life changes within clinical trials. Drug Information Journal, 37, 23–31.

29.

Wyrwich, K. W., Nienaber, N. A., Tierney, W. M., & Wolinsky, F. D. (1999). Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Medical Care, 37(5), 469–478.PubMedCrossRef

30.

Wyrwich, K. W., Tierney, W. M., & Wolinsky, F. D. (1999). Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. Journal of Clinical Epidemiology, 52(9), 861–873.PubMedCrossRef

31.

Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592.PubMedCrossRef

Titel: Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema
Auteurs: Margaret K. Vernon
Anne M. Rentz
Kathleen W. Wyrwich
Martha V. White
Aurelie Grienenberger
Publicatiedatum: 01-09-2009
Uitgeverij: Springer Netherlands
Gepubliceerd in: Quality of Life Research / Uitgave 7/2009
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-009-9509-8

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusions

Log in om toegang te krijgen

Andere artikelen Uitgave 7/2009

Italian translation of the Manchester-Oxford Foot Questionnaire, with re-assessment of reliability and validity

Measuring pain in the context of homelessness

Building PROMIS item banks: librarians as co-investigators

The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS

Readability estimates for commonly used health-related quality of life surveys

Quality of life in Serbian patients with Parkinson’s disease